KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Change in Cash (2016 - 2025)

Historic Change in Cash for Sarepta Therapeutics (SRPT) over the last 15 years, with Q3 2025 value amounting to $100.0 million.

  • Sarepta Therapeutics' Change in Cash rose 15384.43% to $100.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $412.8 million, marking a year-over-year increase of 21873.19%. This contributed to the annual value of $674.6 million for FY2024, which is 22450.9% up from last year.
  • Latest data reveals that Sarepta Therapeutics reported Change in Cash of $100.0 million as of Q3 2025, which was up 15384.43% from $269.7 million recorded in Q2 2025.
  • In the past 5 years, Sarepta Therapeutics' Change in Cash registered a high of $905.2 million during Q4 2024, and its lowest value of -$882.0 million during Q1 2022.
  • Over the past 5 years, Sarepta Therapeutics' median Change in Cash value was -$43.7 million (recorded in 2024), while the average stood at -$46.6 million.
  • Its Change in Cash has fluctuated over the past 5 years, first surged by 171454.53% in 2021, then crashed by 7552657.89% in 2025.
  • Quarter analysis of 5 years shows Sarepta Therapeutics' Change in Cash stood at $517.3 million in 2021, then tumbled by 113.89% to -$71.8 million in 2022, then tumbled by 62.95% to -$117.1 million in 2023, then soared by 873.16% to $905.2 million in 2024, then plummeted by 88.95% to $100.0 million in 2025.
  • Its Change in Cash was $100.0 million in Q3 2025, compared to $269.7 million in Q2 2025 and -$862.1 million in Q1 2025.